Share on StockTwits

Abbott Laboratories (NYSE:ABT) EVP John C. Landgraf sold 1,583 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $39.10, for a total transaction of $61,895.30. Following the completion of the sale, the executive vice president now directly owns 102,421 shares in the company, valued at approximately $4,004,661. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Abbott Laboratories (NYSE:ABT) opened at 38.76 on Thursday. Abbott Laboratories has a one year low of $32.70 and a one year high of $39.86. The stock’s 50-day moving average is $37.99 and its 200-day moving average is $36.48. The company has a market cap of $59.930 billion and a P/E ratio of 23.99.

Abbott Laboratories (NYSE:ABT) last released its earnings data on Wednesday, January 22nd. The company reported $0.58 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.58. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the company posted $1.51 earnings per share. Abbott Laboratories’s revenue was up .4% compared to the same quarter last year. On average, analysts predict that Abbott Laboratories will post $2.20 earnings per share for the current fiscal year.

ABT has been the subject of a number of recent research reports. Analysts at Jefferies Group cut their price target on shares of Abbott Laboratories to $46.00 in a research note on Wednesday, February 12th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note on Thursday, January 23rd. They now have a $40.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Abbott Laboratories from $37.00 to $40.00 in a research note on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $39.42.

Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.